How Gut Bacteria Turn a Fatty Diet Into Colon Cancer Risk

If you have ever been told that a diet heavy in red meat and fat raises your risk of colorectal cancer, but wondered exactly how that link works inside your body, a new study offers the clearest mechanistic answer yet. Published in the journal Gut in January 2026, the research does not just report an association between a Western-style diet and colon tumors, it traces the entire chain from plate to bacteria to tumor and shows each link is causal. For anyone with a family history of colorectal cancer, inflammatory bowel disease, or a general worry about "gut health" and cancer risk, this is the closest science has come to demonstrating the mechanism rather than just observing the correlation.

Key Takeaways

• Gut bacteria, especially Clostridium scindens and Extibacter muris, convert bile acids released by a high-fat, red-meat diet into deoxycholic acid (DCA), and this study shows DCA causes colon tumors in pigs and mice, not just correlates with them.
• A bile-acid-lowering drug, colestyramine, reduced a tumor-related proliferation marker in pigs, supporting the mechanism, but it has never been tested in humans as a cancer preventive and should not be self-prescribed.
• In a pooled human analysis of 1,034 colorectal cancer patients and 1,108 controls, the same DCA-producing bacteria were more common in patients, though this piece of the evidence remains observational.
• Tumors required both the DCA-producing bacteria and an underlying genetic susceptibility in one mouse model, a reminder that diet, microbes, and genetics act together rather than diet alone.

Deoxycholic Acid: The Bacterial Byproduct Behind Colon Tumors

Deoxycholic acid (DCA), a secondary bile acid that gut bacteria make by chemically reworking the primary bile acids your liver releases to digest fat, directly promotes colorectal tumor growth, according to the study, led by researchers at the Technical University of Munich, RWTH Aachen University, and the German Institute of Human Nutrition Potsdam-Rehbrucke, published in Gut in January 2026. The bacteria responsible carry a set of genes called the bai operon (the biochemical toolkit for converting primary bile acids into secondary ones); the two species identified here as the main culprits are Clostridium scindens and Extibacter muris. Earlier research linking DCA to colorectal cancer relied on feeding animals large, non-physiological doses of DCA directly, which does not reflect how the body actually generates it from diet. This study instead built the whole causal chain: diet raises bile acid delivery to the gut, specific bacteria convert it into DCA, and DCA promotes tumor formation. That finding builds on separate work showing DCA can also suppress anti-tumor immune cells directly, adding a second route by which the bile acid could drive cancer.

Western Diet and Colorectal Cancer Risk: Why It Matters

Colorectal cancer is already one of the few cancers where diet is a well-established risk factor, and this research supplies a concrete mechanism for why red meat and saturated fat keep surfacing in that risk profile. In a pooled analysis of published human metagenomic cohorts covering 1,034 colorectal cancer patients and 1,108 controls, bacteria carrying bai-operon genes (specifically C. scindens and a related species, C. hylemonae) were significantly more abundant in the cancer patients. That matters most for people already managing elevated colorectal cancer risk, whether from family history, prior polyps, or inflammatory bowel disease, because it points to a modifiable biological pathway (diet-driven bile acid production) rather than an unchangeable genetic one, even though the human piece of the evidence here is still correlational rather than proof of cause and effect in people.

Pig and Mouse Models: How the Study Proved Causation

The researchers used a genetically engineered pig model (APC1311/+ minipigs) that, unlike standard mouse models, develops tumors in the large intestine much like humans do. In a three-month feeding trial, pigs on a red-meat-and-lard "Western" diet (8 pigs versus 9 controls) developed significantly more and larger colonic polyps, more actively dividing intestinal cells, and sharply higher fecal levels of DCA and a related compound, 12-keto-lithocholic acid. A second feeding trial added a third group of pigs given the same Western diet plus colestyramine, a bile-acid-binding drug (4 to 5 pigs per group); colestyramine reduced the proliferation marker and tended to lower secondary bile acid levels, reinforcing that the bile acids themselves, not diet in some other way, were driving the effect.

To pin down causation more directly, the team turned to gnotobiotic mice (raised germ-free, then colonized with a defined, known set of bacterial species so researchers can add or remove single species and see what changes). Mice colonized with a six-species community either containing or lacking the DCA-producing C. scindens showed that the bacterium alone, even without any cancer-inducing treatment, raised expression of tumor-associated genes and increased epithelial cell proliferation. In a colitis-associated colon cancer model, mice carrying DCA-producing bacteria (either C. scindens or E. muris) developed significantly more tumors than mice without them, and the effect held up independently with two different bacterial species. In a second, genetically distinct cancer-prone mouse model, adding the DCA-producing bacterium increased tumors only when the mice also carried the cancer-susceptibility genes, showing that the bacteria and host genetics both had to be present.

What This Means If You're Watching Your Colon Cancer Risk

This study strengthens, with real causal evidence, the existing general advice to limit red meat and saturated fat as part of colorectal cancer risk management, since less dietary fat means less bile acid delivered to the gut for these bacteria to convert. It does not, however, establish colestyramine or any other bile-acid-lowering drug as a colon cancer preventive for people; that drug arm was one experimental condition in pigs, evaluated for a proliferation marker over months, not a clinical trial for cancer prevention, and nobody should take it, or any bile-acid sequestrant, on the strength of this study. If colorectal cancer risk is something you are actively managing, the more useful conversation to have with a doctor is still the established one: family history, screening schedule, and dietary pattern, not this specific drug or bacterial species.

Limitations: Small Sample Sizes and Correlational Human Data

The gnotobiotic mouse and pig experiments used modest numbers of animals per group, typically 4 to 10, which is standard for this kind of specialized work but still limits statistical power. The human evidence is metagenomic and correlational, showing that DCA-producing bacteria are more common in colorectal cancer patients, not that they caused the cancer in any individual person. The researchers also found that female mice had substantially higher cecal DCA levels than males, though the tumor-promoting effect of DCA-producing bacteria showed up in both sexes. And DCA appeared to boost the number of small, early-stage tumors specifically rather than the growth of already-large ones, which the authors interpret as evidence it promotes tumor initiation rather than progression.

What's Next: Human Trials and the Colestyramine Question

The authors frame their pig and mouse experiments as establishing causality and their human metagenomic data as corroborating, not proving, the same pattern in people. The logical next step, which the study itself does not undertake, is an interventional human trial testing whether reducing bile-acid delivery through diet change, or a medically supervised bile-acid-binding drug, actually lowers precancerous polyp formation or colorectal cancer risk in people. This sits within a fast-growing literature on secondary bile acids in cancer progression, but no such human trial or timeline is described in this paper.

Common Questions

Does this mean cholesterol drugs like colestyramine prevent colon cancer in people? Not yet. Colestyramine only reduced a bile-acid-related proliferation marker in pigs on a specific experimental diet; there is no human trial testing it for colorectal cancer prevention, and it should not be taken for that purpose without a doctor's guidance.

Which gut bacteria were identified as harmful in this study? Clostridium scindens and Extibacter muris, both of which carry bai-operon genes that convert primary bile acids from a fatty diet into the secondary bile acid deoxycholic acid.

Is deoxycholic acid itself dangerous? In the amounts produced by these bacteria in animals eating a high-fat, red-meat diet, yes, it promoted tumor formation in this study, though the human evidence for DCA's role remains observational rather than proven causal.

Does cutting red meat lower these bacteria's cancer-promoting activity? The study did not directly test a diet-change reversal, but its causal chain, in which diet fuels bile acid delivery that these bacteria convert into DCA, is consistent with existing dietary guidance that lowering red meat and saturated fat intake reduces colorectal cancer risk.

References

1. Shaohui Yang, Yu Wang, Lijuan Sheng, Wei Cui, Chenyang Ma (2025). The effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis. Scientific Reports. https://doi.org/10.1038/s41598-024-84801-6
2. Rong Yang, Li Qian (2022). Research on Gut Microbiota-Derived Secondary Bile Acids in Cancer Progression. Integrative Cancer Therapies. https://doi.org/10.1177/15347354221114100